Business Context and Reporting Period
Nanoviricides, Inc. filed this Form 8-K on December 22, 2010, to disclose a "Second Follow-on Closing" of a securities offering. The company is incorporated in Nevada and maintains its principal executive offices in West Haven, Connecticut.
Key Financial Metrics and Transaction Details
- Capital Raised: $2,500,000 aggregate purchase price.
- Instrument: 250,000 shares of Series B Convertible Preferred Stock sold to Seaside 88, LP.
- Purchase Price: $10.00 per share of Series B Preferred Stock.
- Dividend Rate: 10% per annum, payable in cash or Common Stock at a 15% discount to VWAP.
- Transaction Fees: 8% of the gross purchase price paid to Midtown Partners & Co., LLC as a placement agent.
- Conversion Mechanics: 40,000 shares convert automatically every 14 days starting January 3, 2011, based on a discount to the Volume Weighted Average Price (VWAP).
Material Changes and Terms
The filing details a significant capital raise event distinct from prior periods. Key terms include a conversion floor of $0.20 per share of Common Stock; if the VWAP does not exceed this floor, conversion is delayed. Additionally, conversion is contingent upon an effective registration statement for the underlying Common Stock. If conversion fails due to registration issues, the investor holds redemption rights.
Outlook, Risks, and Management Commentary
Management highlighted several material risks associated with this transaction:
- Dilution: Substantial dilution to current stockholders due to the purchase price discount offered to the investor.
- Market Overhang: Potential downward pressure on the stock price from the resale of shares issued upon conversion.
- Execution Risk: Uncertainty regarding the company's ability to satisfy closing conditions on a timely basis.
Investor Verification Checklist
- Verify the current status of the registration statement required for the conversion of Series B Preferred Stock into Common Stock.
- Monitor the daily VWAP of the Common Stock to assess if it meets the $0.20 conversion floor.
- Review the full Letter Agreement (Exhibit 10.1) for specific redemption rights and detailed conversion formulas.
- Confirm the exact amount of the placement fee paid to Midtown Partners & Co., LLC ($200,000 based on 8% of $2.5M).